Pediatric multiple sclerosis (POMS) is a rare but particularly challenging form of the disease. Children and adolescents with MS often experience more relapses, a greater lesion burden on MRI and early-onset cognitive impairment. At the same time, their long-term course is characterized by a delayed but ultimately unstoppable accumulation of disability. For a long time, therapeutic care was limited and restricted to low to moderately effective therapies. In recent years, however, there has been a paradigm shift: highly effective therapies (HETs) are increasingly being used in pediatric patients – with clear benefits for relapse rate, MRI activity and disease progression.
Autoren
- Tanja Schliebe
Publikation
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- A critical analysis of the evidence from 113 studies
Nutrition and depression
- An emerging interface with clinical relevance
Lung cancer and neuroscience
- Acute leukemia: Disease management
Priorities from the perspective of patients and family caregivers
- Bronchodilators for asthma
The early bird … gasps for air
- Chronic kidney disease (CKD)
Triage of high-risk patients – Update 2025
- AAD Annual Meeting: Review
HS and acne – what’s new?
- New perspectives for the optimization of cancer immunotherapy
Nanoparticle-mediated intratumoral gene editing of PD-L1 and galectin-9
- Past, present and future